SUMOylation inhibits FOXM1 activity and delays mitotic transition

Oncogene

Volumn 33, Issue 34, 2014, Pages 4316-4329

  Myatt, S S ^a   Kongsema, M ^a   Man, C W Y ^b   Kelly, D J ^a   Gomes, A R ^a   Khongkow, P ^a   Karunarathna, U ^a   Zona, S ^a   Langer, J K ^a   Dunsby, C W ^a   Coombes, R C ^a   French, P M ^a   Brosens, J J ^c   Lam, E W F ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

breast cancer; cell cycle; chemotherapy; drug resistance; FOXM1; SUMO

Indexed keywords

APC PROTEIN; CYCLIN B1; EPIRUBICIN; FIZZY RELATED PROTEIN; FORKHEAD BOX TRANSCRIPTION FACTOR FOXM1; FORKHEAD TRANSCRIPTION FACTOR; HYBRID PROTEIN; NOCODAZOLE; PACLITAXEL; PROTEIN UBC9; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UBIQUITIN CONJUGATING ENZYME E2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER CELL LINE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COMPUTER MODEL; CONJUGATION; CONTROLLED STUDY; CYTOPLASM; DRUG RESPONSE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MITOSIS; MUTANT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN MOTIF; SUMOYLATION; TREATMENT RESPONSE; UBIQUITINATION;

ANTIBIOTICS, ANTINEOPLASTIC; BINDING SITES; CADHERINS; CELL PROLIFERATION; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FORKHEAD TRANSCRIPTION FACTORS; G2 PHASE CELL CYCLE CHECKPOINTS; HELA CELLS; HUMANS; MCF-7 CELLS; MITOSIS; NOCODAZOLE; PROTEIN TRANSPORT; PROTEOLYSIS; SUMO-1 PROTEIN; SUMOYLATION;

EID: 84906937752     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.546     Document Type: Article

References (54)

1. Monteiro LJ, Khongkow P, Kongsema M, Morris JR, Man C, Weekes D et al. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene 2012; 32: 4634-4645
2. Zhang N, Wu X, Yang L, Xiao F, Zhang H, Zhou A et al. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin Cancer Res 2012; 18: 5961-5971
3. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR et al. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 2012; 33: 1843-1853
4. Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 2010; 70: 5054-5063
5. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: Intrinsic and acquired. Semin Oncol 2008; 35: S1-S14quiz S39
6. Alvarez-Fernandez M, Halim VA, Krenning L, Aprelia M, Mohammed S, Heck AJ et al. Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1. EMBO Rep 2010; 11: 452-458
7. Darieva Z, Bulmer R, Pic-Taylor A, Doris KS, Geymonat M, Sedgwick SG et al. Polo kinase controls cell-cycle-dependent transcription by targeting a coactivator protein. Nature 2006; 444: 494-498
8. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7: 126-136
9. Kim IM, Ramakrishna S, Gusarova GA, Yoder HM, Costa RH, Kalinichenko VV. The forkhead box m1 transcription factor is essential for embryonic development of pulmonary vasculature. J Biol Chem 2005; 280: 22278-22286
10. Millour J, De Olano N, Horimoto Y, Monteiro LJ, Langer JK, Aligue R et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther 2011; 10: 1046-1058
11. De Olano N, Koo CY, Monteiro LJ, Pinto PH, Gomes AR, Aligue R et al. The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment. Mol Cancer Res 2012; 10: 1189-1202
12. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, Jackson SP. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009; 462: 935-939
13. Morris JR, Boutell C, Keppler M, Densham R, Weekes D, Alamshah A et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009; 462: 886-890
14. Werner A, Flotho A, Melchior F. The RanBP2/RanGAP1. *SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase. Mol Cell 2012; 46: 287-298
15. Leisner C, Kammerer D, Denoth A, Britschi M, Barral Y, Liakopoulos D. Regulation of mitotic spindle asymmetry by SUMO and the spindle-Assembly checkpoint in yeast. Curr Biol 2008; 18: 1249-1255
16. Zhang XD, Goeres J, Zhang H, Yen TJ, Porter AC, Matunis MJ. SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol Cell 2008; 29: 729-741
17. Azuma Y, Arnaoutov A, Dasso M. SUMO-2/3 regulates topoisomerase II in mitosis. J Cell Biol 2003; 163: 477-487
18. Hannoun Z, Greenhough S, Jaffray E, Hay RT, Hay DC. Post-Translational modification by SUMO. Toxicology 2010; 278: 288-293
19. Gill G. Post-Translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr Opin Genet Dev 2003; 13: 108-113
20. Jakobs A, Koehnke J, Himstedt F, Funk M, Korn B, Gaestel M et al. Ubc9 fusiondirected SUMOylation (UFDS): A method to analyze function of protein SUMOylation. Nat Methods 2007; 4: 245-250
21. Down CF, Millour J, Lam EW, Watson RJ. Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. Biochim Biophys Acta 2012; 1819: 855-862
22. Sunters A, Fernandez De Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-Treated breast cancer cell lines. J Biol Chem 2003; 278: 49795-49805
23. Ma RY, Tong TH, Cheung AM, Tsang AC, Leung WY, Yao KM. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci 2005; 118: 795-806
24. Behren A, Muhlen S, Acuna Sanhueza GA, Schwager C, Plinkert PK, Huber PE et al. Phenotype-Assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion. Oncogene 2010; 29: 1519-1530
25. Laoukili J, Alvarez-Fernandez M, Stahl M, Medema RH. FoxM1 is degraded at mitotic exit in a Cdh1-dependent manner. Cell Cycle 2008; 7: 2720-2726
26. Zhou Y, Ching YP, Chun AC, Jin DY. Nuclear localization of the cell cycle regulator CDH1 and its regulation by phosphorylation. J Biol Chem 2003; 278: 12530-12536
27. Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS et al. Absence of cancer-Associated changes in human fibroblasts immortalized with telomerase. Nat Genet 1999; 21: 115-118
28. Chang DC, Xu NH, Luo KQ. Degradation of cyclin B is required for the onset of anaphase in mammalian cells. J Biol Chem 2003; 278: 37865-37873
29. Koo CY, Muir KW, Lam EW. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta 2012; 1819: 28-37
30. Wadosky KM, Willis MS. The story so far: Post-Translational regulation of peroxisome proliferator-Activated receptors by ubiquitination and SUMOylation. Am J Physiol Heart Circ Physiol 2012; 302: H515-H526
31. Burrage PS, Schmucker AC, Ren Y, Sporn MB, Brinckerhoff CE. Retinoid X receptor and peroxisome proliferator-Activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression. Arthritis Res Ther 2008; 10: R139
32. Rytinki MM, Palvimo JJ. SUMOylation attenuates the function of PGC-1alpha. J Biol Chem 2009; 284: 26184-26193
33. Ran Y, Liu TT, Zhou Q, Li S, Mao AP, Li Y et al. SENP2 negatively regulates cellular antiviral response by deSUMOylating IRF3 and conditioning it for ubiquitination and degradation. J Mol Cell Biol 2011; 3: 283-292
34. Spengler ML, Brattain MG. Sumoylation inhibits cleavage of Sp1 N-Terminal negative regulatory domain and inhibits Sp1-dependent transcription. J Biol Chem 2006; 281: 5567-5574
35. Kho C, Lee A, Jeong D, Oh JG, Chaanine AH, Kizana E et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 2011; 477: 601-605
36. Sun H, Leverson JD, Hunter T. Conserved function of RNF4 family proteins in eukaryotes: Targeting a ubiquitin ligase to SUMOylated proteins. EMBO J 2007; 26: 4102-4112
37. Yin Y, Seifert A, Chua JS, Maure JF, Golebiowski F, Hay RT. SUMO-Targeted ubiquitin E3 ligase RNF4 is required for the response of human cells to DNA damage. Genes Dev 2012; 26: 1196-1208
38. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008; 10: 538-546
39. Heideker J, Perry JJ, Boddy MN. Genome stability roles of SUMO-Targeted ubiquitin ligases. DNA Repair (Amst) 2009; 8: 517-524
40. Prudden J, Pebernard S, Raffa G, Slavin DA, Perry JJ, Tainer JA et al. SUMOtargeted ubiquitin ligases in genome stability. EMBO J 2007; 26: 4089-4101
41. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, Naismith JH et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem 2001; 276: 35368-35374
42. Knipscheer P, Van Dijk WJ, Olsen JV, Mann M, Sixma TK. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation. EMBO J 2007; 26: 2797-2807
43. Hakli M, Karvonen U, Janne OA, Palvimo JJ. SUMO-1 promotes association of SNURF (RNF4) with PML nuclear bodies. Exp Cell Res 2005; 304: 224-233
44. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al. Arsenic degrades PML or PML-RARalpha through a SUMO-Triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10: 547-555
45. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, Lam EW. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 2008; 7: 2022-2032
46. Jones MC, Fusi L, Higham JH, Abdel-Hafiz H, Horwitz KB, Lam EW et al. Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. Proc Natl Acad Sci USA 2006; 103: 16272-16277
47. Bailey D, O'Hare P. Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J Biol Chem 2004; 279: 692-703
48. Xue Y, Zhou F, Fu C, Xu Y, Yao X. SUMOsp: A web server for sumoylation site prediction. Nucleic Acids Res 2006; 34: W254-W257
49. Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, Fernandez De Mattos S et al. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol 2008; 28: 5886-5898
50. Collado M, Medema RH, Garcia-Cao I, Dubuisson ML, Barradas M, Glassford J et al. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 2000; 275: 21960-21968
51. Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, Leung WY et al. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett 2001; 507: 59-66
52. Lam EW, Watson RJ. An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription. EMBO J 1993; 12: 2705-2713
53. Alibhai D, Kelly DJ, Warren S, Kumar S, Margineau A, Serwa RA et al. Automated fluorescence lifetime imaging plate reader and its application to Forster resonant energy transfer readout of Gag protein aggregation. J Biophotonics 2013; 6: 398-408
54. Warren SC, Margineanu A, Alibhai D, Kelly DJ, Talbot C, Alexandrov Y et al. Rapid global fitting of large fluorescence lifetime imaging microscopy datasets. PLoS One 2013; 8: E70687